According to the Yale School of Medicine data in April 2024, research has revealed that biosimilar manufacturers could sell insulin at prices 97% lower than current U.S
Retatrutide is getting serious attention as a next-generation weight loss drug
It does not provide exogenous GLP-1
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist that activates: GLP-1 (glucagon-like peptide-1) receptor GIP (glucose-dependent insulinotropic polypeptide) receptor Glucagon (GCG) receptor This triple G mechanism targets multiple pathways for appetite control, insulin sensitivity, glucose regulation, and energy/fat metabolismpotentially offering greater effects than dual (GLP-1/GIP) or single agonists
Response may vary across age groups, though evidence for consistent age-related differences in onset of action is limited
348 Similarly, in human chondrocytes stimulated by TNF, GLP-1 analogs (such as liraglutide) showed an anti-catabolic effect, reducing the mRNA expression of MMP-3, MMP-13, and ADAMTS5
